hydralazine and misonidazole

hydralazine has been researched along with misonidazole in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19908 (66.67)18.7374
1990's4 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown, JM; Lemmon, MJ1
Chaplin, D; Durand, R; Guichard, M; Lespinasse, F; Trotter, M1
Adams, GE; Bowler, J; Bremner, JC; Stratford, IJ1
Siemann, DW1
Adams, GE; Godden, J; Howells, N; Stratford, IJ1
Adams, GE; Cole, S; Stratford, IJ1
Cole, S; Robbins, L1
Chaplin, DJ2
Adams, GE; Godden, J; Howells, N; Nolan, J; Stratford, IJ; Timpson, N1
Chaplin, DJ; Horsman, MR; Overgaard, J1
Acker, B; Chaplin, DJ1

Other Studies

12 other study(ies) available for hydralazine and misonidazole

ArticleYear
Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue.
    International journal of radiation oncology, biology, physics, 1991, Volume: 21, Issue:6

    Topics: Animals; Carbon Radioisotopes; Carcinoma, Squamous Cell; Cell Hypoxia; Drug Administration Schedule; Female; Hydralazine; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Radiotherapy Dosage

1991
The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1991, Volume: 20, Issue:2

    Topics: Animals; Cell Hypoxia; Cell Line; Humans; Hydralazine; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Radiation Tolerance; Rats; Regional Blood Flow; Transplantation, Heterologous

1991
Bioreductive drugs and the selective induction of tumour hypoxia.
    British journal of cancer, 1990, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Constriction; Hydralazine; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Mitomycins; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Triazines

1990
Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
    British journal of cancer, 1990, Volume: 62, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cyclophosphamide; Drug Synergism; Female; Hydralazine; Lomustine; Melphalan; Mice; Mice, Inbred C3H; Misonidazole; Sarcoma, Experimental; Stem Cells

1990
Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
    International journal of radiation biology, 1989, Volume: 55, Issue:3

    Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Oxygen; Radiation-Sensitizing Agents

1989
Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
    International journal of radiation biology, 1989, Volume: 56, Issue:5

    Topics: Animals; Cell Hypoxia; Combined Modality Therapy; Constriction; Female; Hydralazine; Melanoma; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Radiation-Sensitizing Agents; Transplantation, Heterologous

1989
Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1989, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Colonic Neoplasms; Combined Modality Therapy; Female; Humans; Hydralazine; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Oxidation-Reduction; Oxygen; Radiation-Sensitizing Agents; Radiotherapy; Transplantation, Heterologous

1989
Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy.
    Journal of the National Cancer Institute, 1989, Apr-19, Volume: 81, Issue:8

    Topics: Animals; Antineoplastic Agents; Aziridines; Drug Synergism; Female; Hydralazine; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Misonidazole; Mitomycins; Neoplasms, Experimental; Regional Blood Flow

1989
Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
    British journal of cancer, 1988, Volume: 58, Issue:2

    Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Hydralazine; Male; Melphalan; Mice; Mice, Inbred C3H; Misonidazole; Oxygen Consumption; Sarcoma, Experimental; Time Factors

1988
The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.
    Acta oncologica (Stockholm, Sweden), 1988, Volume: 27, Issue:6b

    Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Hyperthermia, Induced; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred DBA; Misonidazole

1988
Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Radiation research, 1988, Volume: 115, Issue:2

    Topics: Animals; Cell Survival; Combined Modality Therapy; Female; Hydralazine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Misonidazole; Radiation-Sensitizing Agents; Regional Blood Flow; Vasodilator Agents

1988
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
    International journal of radiation oncology, biology, physics, 1987, Volume: 13, Issue:4

    Topics: Animals; Cell Survival; Cells, Cultured; Female; Hydralazine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Misonidazole; Radiation-Sensitizing Agents

1987